Business Context and Reporting Period
This Form 8-K is filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) for the reporting period of January 28, 2005. The filing discloses a material definitive agreement, unregistered sales of equity securities, and a change in the company's certifying accountant.
Key Financial Metrics and Capital Structure
- Capital Raised: Approximately $2.9 million in aggregate proceeds from a private placement.
- Securities Issued: 1,470,718 shares of common stock and 367,681 warrants sold as "Units" at $1.95 per Unit.
- Warrant Terms (Investors): Immediately exercisable at $2.95 per share; each warrant covers one-quarter share; five-year expiration.
- Compensation to Selling Agents: $193,438 in cash, 123,659 warrants (exercisable at $2.15/share), and 24,461 shares of common stock.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for operating revenue, net income, operating cash flow, or debt levels.
Material Changes and Corporate Actions
- Private Placement: Closed on January 28, 2005, relying on Section 4(2) and Rule 506 exemptions for accredited investors.
- Registration Rights: Entered into an agreement to file a registration statement within 120 days for the resale of shares and warrant-exercise shares.
- Accountant Resignation: Baum & Company, PA resigned as principal independent public accounting firm effective January 28, 2005. Their tenure covered the period from January 11, 2003, to January 28, 2005.
- Accountant Appointment: Lazar Levine & Felix LLP was engaged as the new principal independent registered public accounting firm on January 28, 2005.
Management Commentary, Risks, and Contingencies
- Audit History: Reports by the former accountant (Baum & Company) contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- Disagreements: There were no disagreements with the former accountant on accounting principles, practices, or disclosures.
- Consultation with New Accountant: The company did not consult with the new accountant (LLF) regarding accounting principles or reportable events prior to engagement.
- Risks: The filing does not explicitly detail operational risks beyond the standard implications of a private placement and auditor change.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-issuance to assess dilution impact.
- Confirm the status of the registration statement filing required within 120 days of the closing.
- Review the financial statements audited by Baum & Company for the year ended January 31, 2004, to understand the baseline financial health prior to the capital raise.
- Investigate the rationale for the change in auditors, despite the lack of reported disagreements.
- Clarify the company's current cash runway given the $2.9 million raise and lack of reported operating revenue in this filing.